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Abstract
Background: The purpose of the study was the application and evaluation of array Comparative Genomic
Hybridization (array CGH) in selected cases during prenatal diagnosis. Array CGH was applied in 25 fetal samples
out of which 15 had normal karyotypes and abnormal ultrasound findings and 10 had apparently balanced
structural aberrations with or without abnormal ultrasound findings. DNA was extracted from peripheral blood,
chorionic villi samples (CV) and amniotic fluid. Bacterial Artificial Chromosome (BAC) array CGH (Cytochip,
BlueGnome Ltd.) of 1 Mb was applied and results were confirmed with either Fluorescence In Situ Hybridization
(FISH), Multiplex Ligation-dependant Probe Amplification (MLPA) or Real-Time PCR.
Results: Three out of 25 samples (12%), referred for prenatal array CGH, were found to carry copy number
alterations. The number of cases with clinically significant alterations was 2/25 (8%), while one (4%) was of
uncertain clinical significance. Two benign Copy Number Variations (CNVs) were also found in 1/25 cases (4%).
Conclusions: The outcome of this study indicates the ability of array CGH to identify chromosomal abnormalities
which cannot be detected during routine prenatal cytogenetic analysis, therefore increasing the overall detection rate.
Background
During the last 30 years conventional cytogenetics using
the G-banded karyotype has been the method of choice
for prenatal diagnosis, accurately detecting chromosomal
abnormalities larger than 5 Mb. However, it is inefficient
in detecting sub-microscopic deletions and duplications
that are often associated with malformations and mental
retardation. Such subtle abnormalities which cannot be
detected with the conventional G-banded karyotype can
be investigated and identified by array-based Comparative
Genomic Hybridization (array CGH) [1,2].
Array CGH is established as the method of choice for
fast and accurate detection of unbalanced structural and
numerical chromosomal abnormalities [2,3]. During the
last few years, the implementation of array CGH in
postnatal diagnosis has been very extensive and efficient.
Many reports have demonstrated the sensitivity, specifi-
city and accuracy of this methodology detecting large
and small-size imbalances [4-7]. Array CGH in postnatal
diagnosis allows accurate diagnosis, characterization of
syndromes, phenotype and genotype correlation, preven-
tion, prognosis and better clinical management. The
detection rate of array CGH in postnatal diagnosis was
estimated between 7-11% in patients with mental retar-
dation/Multiple Congenital Abnormalities (MCA) and
with normal or no karyotype [4-7].
On the other hand, array CGH has a limited use in pre-
natal diagnosis. This is mainly due to the fact that CNVs
detected in patients with uncharacterized genetic syn-
dromes cannot be clearly classified as benign or patho-
genic. Even though the high resolution of analysis allows
the identification of smaller genetic imbalances the prob-
ability of identifying a benign variant is increased, thus
imposing challenges for the interpretation of results [4].
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prenatal diagnosis provide limited information as to
where and under what conditions such screening should
be used. These microarray platforms (Baylor College of
Medicine Chromosomal Microarrays Versions 4.0, 5.0
and 6.0) targeted genomic disorders, subtelomeric as well
as pericentromeric regions. Rickman et al. [8] used a tar-
geted array CGH platform to analyze DNA samples
extracted from amniotic fluid (AF) and chorionic villi
(CV) cultures in pregnanciesw i t hk n o w nc y t o g e n e t i c
abnormalities and confirmed 29 out of 30 cases. Sahoo et
al. 2006 [9] carried out array CGH in 98 prenatal samples
simultaneously with G banded karyotype and detected
clinically significant copy number changes in 5.1% of the
samples. All five abnormalities (four cases with trisomy
21 and one case with der(7)t(3;7)) were diagnosed with
both karyotype and array CGH methodologies. In the
same study two additional de novo abnormalities (2.4%)
were detected involving CNV regions of uncertain clini-
cal significance [9]. In another study, 151 prenatal cases
with normal karyotype were retrospectively screened and
two causative rearrangements were identified, resulting
in a diagnostic yield of 1.3% [5]. The frequencies of
apparently benign alterations and findings of unclear sig-
nificance were 7.9% and 0.6% respectively, after parental
analysis [5]. Recently, in another study where targeted
array CGH was applied in the evaluation of 300 prenatal
samples, it was reported that 58 CNVs were detected. Of
those, 15 (5%) were clinically significant chromosome
alterations, 3 (1%) were of uncertain clinical significance,
and 40 (13.3%) were benign CNVs [10]. Vialard et al.
2009 used targeted array CGH to screen for classic
microdeletion syndromes and subtelomeric rearrange-
ments in 39 fetuses with MCA after termination of preg-
nancy. Of those 39 fetuses, 37 had a normal karyotype
a n dt w oh a dade novo unbalanced karyotype that could
not be characterized with conventional cytogenetic meth-
o d s .A sar e s u l tf r o mt h i ss t u d y ,t w ode novo unbalanced
karyotypes were characterized by array CGH and four
additional abnormalities were diagnosed. In fetuses with
normal karyotypes but MCAs the detection rate was
10.8% (4/37) [11].
Valduga et al. 2010 screened 50 fetuses with multiple
malformations and a normal karyotype with 44 K oligo-
nucleotide array (Agilent Technologies) and identified
causative imbalances in five out of 50 fetuses (10%). In
the same study a new polymorphic region was also
found in one out of 50 fetuses (2%) [12].
Coppinger et al. 2009 [13] used either whole-genome
Bacterial Artificial Chromosome (BAC) and oligonucleo-
tide microarrays or targeted BAC microarrays on 182
and 62 prenatal cases respectively without previously
known chromosome abnormalities or family history of a
parent with a known chromosome rearrangement. Array
analysis identified clinically significant findings in five
out of 182 cases (2.7%) and a finding of unclear signifi-
cance in one case (0.5%). In addition, 16 cases (8.8%)
were found to have benign copy number variants. In the
same study targeted array CGH analysis demonstrated
detection rates of 0.9% for clinically significant abnorm-
alities, 0.5% for findings of unclear significance and 8.0%
for benign CNVs.
In this study, we present our experience of using
whole-genome 1 Mb BAC array CGH during prenatal
diagnosis in selected cases with abnormal ultrasound
findings or an apparently balanced structural aberration
and provide a summary of our results. We attempt to
e v a l u a t et h er o l eo fw h o l e - g e n o m eB A C - b a s e da r r a y
CGH in prenatal diagnosis to gain a better understanding
of its clinical utility.
Materials and methods
Patients and Samples
All samples included in this study were received
between January 2007 and November 2009 for prenatal
diagnosis using G-banded karyotype and whole-genome
array CGH methodology. Among the 1305 prenatal
samples received within the above period only 25 cases
were specifically referred by the physicians for array
CGH prenatal diagnosis. Of those 25 cases, 15 had nor-
mal karyotypes and abnormal ultrasound findings and
10 had an apparently balanced structural aberration,
with or without abnormal ultrasound findings (Table 1).
All prospective parents were offered genetic counseling
by the referring clinician and consented prior to the
testing. Of the 25 fetal samples 9 were Chorionic Villi
(CV) and 16 were amniotic fluid. Blood samples for
DNA extraction and subsequent testing were also
received from both future parents.
G-banded karyotype and array CGH
All samples (CV, amniotic fluid and blood) were cultured
and G-banded for karyotyping using standard cytogenetic
methodologies. Fluorescence In Situ Hybridization
(FISH) was performed using commercially available
probes according to the manufacturer’s protocol (VYSIS,
Co, Downers Grove, IL, USA). DNA was extracted from
CV and amniotic fluid cultured cells as well as from
uncultured blood using the Qiagen Mini and Blood Midi
Kit respectively (Qiagen, Valencia, CA, USA) and con-
centration was measured using the NanoDrop spectro-
photometer (NanoDrop Technologies, Inc., USA).
For array CGH, the test and reference DNA of the
same gender were co-hybridized to the Cytochip (Blue-
Gnome, Ltd., UK,) whole-genome BAC array, as pre-
viously described [14]. The Cytochip BlueGnome array is
a commercially available whole-genome BAC array with
a median resolution of 0.5-1 Mb (Cytochip, BlueGnome
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Sample Type (N = 25), CV: 9, Amniotic Fluid: 16
Case
No.
Reason for
Referral for
aCGH
U/S Findings Sample
Type
Karyotype aCGH
Result
Inh. Array Result/Pregnancy Outcome
1 U/S
abnormalities
Increased NT CV 46,XY Normal N/A Normal constitution. Healthy baby.
2 U/S
abnormalities
Hypoplastic
Nasal Bone
AF 46,XY Dup,
Dup,
Del
Maternal Two familial dups on chromosome 9 of 0.3
Mb and 0.15 Mb of unclear significance
but considered to represent
polymorphisms. A deletion on
chromosome 17 of 1.1 Mb at the PMP22
gene consistent with HNPP. Healthy baby.
3 Familial
balanced
rearrangement
Normal CV 46,XX,inv(3)(p11.2q11.2)pat Normal Paternal Normal constitution. Healthy baby.
4 Familial
balanced
rearrangement;
U/S
abnormalities
Hydronephrosis,
Aortic arch
AF 46,XX,inv(20)(q13.1q13.3)pat Normal Paternal Normal constitution. Healthy baby.
5 Familial
balanced
rearrangement
Normal CV 46,XY,inv(2)(p11.2q34)mat Normal Maternal Normal constitution. Healthy baby.
6 De novo
balanced
rearrangement;
U/S
abnormalities
Echogenic heart;
Clinodactyly
AF 46,XY,t(5;16)(q33;q24)dn Normal De novo Normal constitution. Healthy baby.
7 De novo
balanced
rearrangement
Normal AF 46,XX,t(2;12)(q31;q13)dn Normal De novo Normal constitution. Healthy baby.
8 De novo
balanced
rearrangement;
U/S
abnormalities
Increased NT AF 46,XX,t(3;14)(p13;q11.2)dn Normal De novo Normal constitution. Healthy baby.
9 De novo
balanced
rearrangement;
U/S
abnormalities
Increased NT AF 46,XY,t(17;21)(p11.2;q22.3)dn Normal De novo Normal constitution. Unknown pregnancy
outcome.
10 De novo
balanced
rearrangement
Normal CV 46,XY,t(1;2)(q25;q21)dn Del De novo De novo deletion on chromosome 1 of 0.2-
1.35 Mb of uncertain clinical significance
Elective termination of pregnancy.
11 De novo
balanced
rearrangement
Normal AF 46,XY,t(3;8) (p13;q24.22)dn Normal De novo Normal constitution. Healthy baby.
12 De novo
balanced
rearrangement;
U/S
abnormalities
Short Femur AF 46,XX,t(11;13)(p10;q10)dn Normal De novo Normal constitution. Unknown pregnancy
outcome
13 U/S
abnormalities
Myocardiopathy CV 46,XY Normal N/A Normal constitution Elective termination of
pregnancy.
14 U/S
abnormalities
Nasal Bone
hypoplasia;
Cardiac
Anomalies
AF 46,XY Normal N/A Normal constitution. Healthy baby.
15 U/S
abnormalities
Tumor on left
ear
AF 46,XY Normal N/A Normal constitution. Healthy baby.
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Page 3 of 10Ltd., UK, Version 2.0). The reference DNAs were derived
from pooled peripheral blood leukocytes of phenotypi-
cally normal males and females (Promega, Madison,
WI, USA).
The array has been designed to provide redundancy with
high sensitivity and specificity for the detection of clini-
cally significant genomic imbalances. DNA labeling and
hybridization were performed as previously described [14].
The arrays were scanned with Agilent G2565B scanner
and image files were quantified using Agilent’sF e a t u r e
extraction software (V9.5.3.1).
Array Data and Confirmatory Analysis
Array data were analyzed using Bluefuse software ana-
lysis (BlueGnome Ltd., UK). All detected copy number
changes were compared to known aberrations listed in
publically available databases, such as ENSEMBL
(Ensembl: http://www.ensembl.org), DECIPHER
(http://decipher.sanger.ac.uk) and the Database of
Genomic Variants (DGV, http://projects.tcag.ca/varia-
tion/) using NCBI136/hg18 UCSC assembly. Parental
samples were analyzed by array CGH, where needed,
to specifically exclude the presence or absence of
CNVs detected in the fetus. For all copy number varia-
tions found, confirmatory FISH, Multiplex Ligation-
dependant Probe Amplification (MLPA) or Real Time
Polymerase Chain Reaction (RT-PCR) were performed
using previously described standard procedures
[15-17].
Results
Array GCH analysis and Data Interpretation
Out of the 25 cases, three (cases 2, 10 and 25), were
found to have genomic imbalances (12%) (Table 1). Two
were clinically significant (2/25-8%) and one was of
uncertain clinical significance (1/25-4%). In addition, in
one of the cases (1/25-4%) in which a clinically signifi-
cant imbalance was detected, two benign CNVs were
also found (case 2).
Case 2 was initially referred for prenatal cytogenetic
diagnosis because of advanced maternal age. The fetal
karyotype was normal but as abnormal ultrasound find-
ings were present in a subsequent screening, it was then
referred for array CGH testing. During counseling the
Table 1 Prenatal microarray CGH case overview (Continued)
16 U/S
abnormalities
Bilateral
Hydronephrosis;
Pyelic right
kidney
AF 46,XY Normal N/A Normal constitution. Healthy baby.
17 U/S
abnormalities
Nasal bone
hypoplasia; short
limbs; echogenic
bowel; FGR
AF 46,XY Normal N/A Normal constitution. Healthy baby.
18 U/S
abnormalities
Short limbs AF 46,XY Normal N/A Normal constitution Elective termination of
pregnancy.
19 U/S
abnormalities
Increased NT;
talipes
CV 46,XY Normal N/A Normal constitution. Healthy baby.
20 U/S
abnormalities
Spine
deformities;
talipes; short
femur
CV 46,XY Normal N/A Normal constitution Elective termination of
pregnancy.
21 U/S
abnormalities
FGR; Single
umbilical artery;
Pyelic cyst
CV 46,XX Normal N/A Normal constitution. Healthy baby.
22 U/S
abnormalities
Increased NT CV 46,XX Normal N/A Normal constitution. Healthy baby.
23 U/S
abnormalities
FGR AF 46,XX Normal N/A Normal constitution. Healthy baby.
24 U/S
abnormalities
Facial Cleft; Fetal
abnormality
AF 46,XX Normal N/A Normal constitution Premature delivery at
29 weeks due to preeclampsia. No follow
up possible at the moment.
25 U/S
abnormalities
Increased NT AF 46,XX Dup Parents
not
available
Dup of 0.7 Mb found on chromosome 22,
includes the Velocardiofacial/DiGeorge
Syndrome region, consistent with the
22q11.2 microduplication syndrome.
Pregnancy complications resulted in fetal
death.
CV, Chorionic Villus Sample; AF, Amniotic Fluid Sample; U/S, ultrasound abnormalities; FGR, Fetal growth retardation; aCGH, array Comparative Genomic
Hybridization; dup, duplication; del, deletion; NT, Nuchal Thickening; Inh., Inheritance; N/A, Not Applicable
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mild polyneuropathy, which included episodes of numb-
ness and weakness. Two duplications of 0.3 Mb and
0.15 Mb, and a deletion of 1.1 Mb in size were detected
(Figure 1). Array CGH analysis in the parents showed
that all three findings were of maternal origin. The 0.3
Mb and 0.15 Mb duplications were located on chromo-
some 9 between 6362145-6650803bp and 2589860-
2728609bp, respectively. They were not consistent
with the mother’s phenotype and probably represent
non-causative or benign CNVs. However, the 1.1 Mb
deletion was found at the PMP22 gene located on
14324518-15415748bp on chromosome 17 (17p11.2)
and is consistent with Hereditary Neuropathy with
Liability to Pressure Palsies (HNPP) which is a poly-
neuropathy with or without symptoms, thus confirming
the clinical findings in the mother who did not present
any other clinical features besides the ones described for
HNPP. The deletion was confirmed with MLPA in both
the fetus and the affected parent. After counseling the
parents decided to continue the pregnancy and they
gave birth to a healthy baby boy.
Case 10 was originally referred for prenatal cytogenetic
diagnosis because of advanced maternal age. An appar-
ently balanced translocation was found during cytoge-
netic analysis. Parental chromosomal analysis revealed
normal karyotypes and therefore the balanced transloca-
tion was classified as de novo. Array CGH was performed
to exclude any imbalances derived from the transloca-
tion. A deletion of 0.2-1.35 Mb corresponding to clone
RP11-440G22 located on 190230845bp on chromosome
1 (1q31.2) was detected at the translocation breakpoint
(Figure 2). Both parents were analyzed with the same
array CGH platform and were negative for the above
deletion. Array-CGH results for patient and parents were
confirmed using RT-PCR. The deletion was not listed in
the ENSEMBL database (http://www.ensembl.org) and its
clinical significance is unclear. The deleted region does
not contain any genes causing known syndromes, how-
ever based on the fact that the deletion was de novo in
Figure 1 Array CGH (Cytochip BAC array) showing a deletion on the short arm of chromosome 17 (17p11.2). Lines show the deleted
clones and their physical location. The + or - signs indicate the presence or absence of the clone stated.
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breakpoint and that there is an entry with a similar aber-
ration in the DECIPHER database, we concluded that the
deletion is probably of clinical significance and there was
an increased risk for a phenotypic effect of the fetus.
However, as there is no definitive evidence for the causal-
ity of this aberration, we categorized it as an abnormality
of uncertain clinical significance. Pregnancy outcome was
elective termination.
Case 25 was initially referred for chromosomal analy-
sis due to advanced maternal age and increased Nuchal
Translucency on ultrasound. When the karyotype was
found to be normal it was referred for array CGH analy-
sis. A 0.7 Mb duplication was detected which is located
on 17552768-18223647bp of chromosome 22 (Figure 3).
The duplication is of clinical significance because it falls
within the Velocardiofacial/DiGeorge syndrome region
and is consistent with the 22q11.2 microduplication syn-
drome [18]. The syndrome has a variable phenotype and
the causative duplication can be either familial or
de novo. The inheritance of this duplication could not
be evaluated because parental screening was not per-
formed. There were pregnancy complications which
resulted in fetal death and the parents did not wish to
continue the investigation.
Discussion
This study evaluates the clinical application of whole-
genome array CGH in 25 selected samples during prena-
tal diagnosis. Array CGH is the most advanced method
yet for assessing genomic imbalances associated with
genetic diseases. The implementation of genome-wide
array CGH in postnatal diagnosis is the method of choice
providing higher diagnostic yields and many other major
advantages. However, array CGH in prenatal diagnosis is
of limited use. This is mainly because trisomies and other
large abnormalities (>5 Mb) are most commonly found
and can easily be detected by conventional karyotyping
Figure 2 Array CGH (Cytochip BAC array) showing a deletion on the long arm of chromosome 1 (1q31.2). Line shows the deleted clone
as well as the previous and next non-deleted clones and their physical location. The + or - signs indicate the presence or absence of the clone
stated.
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small size (<5 Mb) abnormalities usually found by array
CGH may be unclear because there are syndromes
caused by small size segmental imbalances that have not
yet been characterized and reported. In addition,
amongst the imbalances that are detected, there is a sig-
nificant number of CNVs that have not yet been charac-
terized and we are still not aware of their clinical
significance, their function, their association with abnor-
mal phenotypes and their implication in diagnosis
[19,20]. Such uncertain findings may pose challenges for
the clinical cytogenetic laboratory to accurately report
and interpret the results of array CGH prenatal testing.
As a consequence, the referring clinician may have diffi-
culty in predicting the outcome, estimating recurrence
risks and offering proper genetic counseling and clinical
management. Furthermore, the anxiety of prospective
parents increases while waiting for the results of such
highly informative testing [21]. Another important
limitation of prenatal array CGH is the fact that low level
mosaicism can be present in prenatal screening but may
remain undetected. The ability of array CGH to detect
and evaluate low-level mosaicism is not yet known. The
lowest mosaicism grade that has been detected by 1 Mb
array-CGH analysis is as low as 8% [22].
In our study, we applied array CGH in only a limited
highly selective number of cases (N = 25) that were ori-
ginally referred for cytogenetic prenatal diagnosis (N =
1305) and were found normal or with an apparently
balanced translocation or inversion. The first group con-
sisted of cases which fetal medicine specialists had evalu-
ated as high risk for chromosomal abnormalities because
of abnormal ultrasound findings, while the second group
consisted of cases in which an apparently balanced trans-
location or inversion was detected (Table 1). In this study
w eu s e dB A Ca r r a y sf o ro u rs c r e e n i n gf o ran u m b e ro f
reasons. The design of these arrays is more diagnostically
oriented with high coverage in disease regions and less
Figure 3 Array CGH (Cytochip BAC array) showing a duplication on the long arm of chromosome 22 (22q11.2).L i n e ss h o wt h e
duplicated clones as well as the previous and next non-duplicated clones and their physical location. The + shows the presence of the clone
and the ++ sign indicates duplication of the clone.
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form for all our diagnostic cases allowing an easy inter-
pretation of results.
In a total of 25 prenatal samples three (12%) were
found with confirmed copy number alterations. The
number of cases with clinically significant alterations
was 2/25 (8%), while the number of findings of uncer-
tain clinical significance was 1/25 (4%). Even though
comparison with the other five available studies should
be done with caution as different parameters are used,
the frequency of confirmed abnormalities is significant
[5,9-12]. In previous studies the detection rate of clini-
cally significant confirmed abnormalities ranged between
1.3-7.4%, while the detection rate of findings with
unclear clinical significance was between 0.6-3.7%
[5,9,10]. When evaluating the detection rate of prenatal
diagnosis with array CGH one must take into considera-
tion the design and resolution of the array used, the rea-
son for referral, whether the G-banded karyotype was
found normal and, finally, if non-pathogenic benign var-
iants (CNVs) have been included when estimating the
detection rate. Taking into account our results and
those of others, we estimated that during prenatal diag-
nosis when array CGH is applied approximately up to
12% of small genomic imbalances with known or
unclear clinical significance are expected to be identi-
fied. There is no doubt that such a detection rate is sig-
nificant and adds important diagnostic information for
prenatal genetic counseling and risk assessment. In the
present study the detection rate of clinically significant
aberrations is 8%. Although an aberration may not
appear pathogenic, future studies may result in identifi-
cation of novel causative imbalances. These findings are
important for research and can provide valuable data for
disease gene identification.
In our study, all three abnormalities identified following
a specific referral for array CGH prenatal examination
were small in size (0.2-1.5 Mb) and were not detected by
conventional cytogenetic prenatal testing. This demon-
strates that the application of array CGH during prenatal
diagnosis increases resolution and improves the detection
rate. In two of the cases (cases 2 and 25, Table 1), the
abnormalities were clearly found to be consistent with spe-
cific genetic conditions. In case 2 the 17p11.2 deletion
detected (HNPP) was not related to the ultrasound find-
ings and can be characterized as a coincidental finding. In
case 25 the 22q11.2 microduplication detected may or
may not be associated with the ultrasound findings. The
22q11.2 microduplication syndrome has a variable pheno-
type and it is therefore difficult to make a correlation with
the ultrasound findings when detected prenatally. Array
CGH is increasingly used in prenatal testing; additional
cases of prenatal 22q11.2 microduplication will eventually
be detected and reported and may lead to an association
with the ultrasound findings if any. In case 10, the
abnormality was found to be a de novo deletion, with an
entry in DECIPHER featuring a similar aberration. It was
therefore concluded that there is an increased risk for a
phenotypic effect of the fetus, even though the abnormal-
ity was of uncertain clinical significance. In all three cases,
prenatal array CGH analysis added very important diag-
nostic information for prenatal genetic counseling and risk
assessment. Elective termination of the pregnancy was
only decided by the parents in case 10. Our data as well as
other studies indicate that pregnancies with ultrasound
abnormalities or de novo apparently balanced rearrange-
ments are good candidates for prenatal diagnosis with
array CGH because a large number of clinically significant
cryptic abnormalities can be detected by combining ultra-
sound investigation and array CGH analysis [22-24]. The
estimated risk for phenotypic abnormalities in carriers of
de novo reciprocal translocations detected at prenatal diag-
nosis is 6%; by implementing array CGH and therefore
excluding submicroscopic changes, a lower and more
accurate phenotypic risk can be reported to the patient
[25]. In familial reciprocal translocations as suggested by
Sismani et al. 2008 [24] cryptic copy number changes at
least at the resolution of 1 Mb, do not constitute a major
cause for phenotypic abnormalities present in these
patients where the carrier parent has a normal phenotype.
The same study also demonstrated that a genomic imbal-
ance was present in a familial case of reciprocal transloca-
tion where both the carrier parent and child had abnormal
phenotypes. Therefore, array CGH should be carried out
in cases of de novo balanced translocations, as well as in
cases where the carrier parent is also affected.
Before we attempt evaluation of the use of whole-gen-
ome array CGH for prenatal diagnosis we should stress
that pre-test education and counseling is paramount. It
should be supplemented by consent documents which
should include a written summary of the testing process,
potential benefits and limitations, co-incidental findings,
possible testing outcome and sources of educational
material. Furthermore, the laboratory director, the refer-
ring clinician and the genetic counselor must be avail-
able for inquiries before and after testing [21]. These
measures will facilitate analysis, resolve potential pro-
blems and limit anxiety.
Conclusion
At a resolution of 1 Mb, the application of BAC array
CGH in selected cases during prenatal diagnosis allowed
the detection of 8% of known clinically significant
alterations and 4% of clinically uncertain alterations,
which is comparable to other published data. Our study
supports that pregnancies with ultrasound abnormalities
or apparently balanced translocations or inversions are
very good indications for prenatal diagnosis with array
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demonstrating that array CGH is a method of high reso-
lution and detection rate, and adds important diagnostic
information for prenatal genetic counseling and risk
assessment. Currently, clinical application of array CGH
a sau n i v e r s a lr o u t i n et e s tf o rprenatal diagnosis is pre-
mature. Further investigation will allow an evaluation
between the overall diagnostic yield of array CGH over
routine prenatal testing with conventional karyotype, as
well as cost effectiveness issues.
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